Geron Corporation Total Assets
Geron Corporation total assets. Based on the latest financial reports, Geron Corporation (GERN) holds total assets worth $519.01 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Geron Corporation market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Geron Corporation (1996–2025)
Total assets of Geron Corporation from 1996 to 2025. This chart illustrates how Geron Corporation's total assets have evolved over time, based on quarterly financial data. See current stock price of Geron Corporation for real-time trading data and today's change.
Geron Corporation - Asset Composition Analysis
Geron Corporation Total Assets Breakdown (December 2025)
Geron Corporation total assets breakdown as of December 2025. Geron Corporation's total assets of $519.01 Million consist of 91.2% current assets and 8.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.9% |
| Accounts Receivable | $39.23 Million | 6.9% |
| Inventory | $116.64 Million | 20.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Geron Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Geron Corporation short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Geron Corporation's current assets represent 91.2% of total assets in 2025, an increase from 86.8% in 1996.
- Cash Position: Cash and equivalents constituted 13.9% of total assets in 2025, down from 43.1% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 20.4% of total assets.
Geron Corporation Competitors by Total Assets
Key competitors of Geron Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Geron Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.92 | 7.87 | 4.66 |
| Quick Ratio | 5.16 | 6.79 | 4.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $416.01 Million | $441.31 Million | $140.88 Million |
Geron Corporation - Advanced Valuation Insights
This section examines the relationship between Geron Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | $570.54 Million |
| Market Capitalization | $596.92 Million USD |
Valuation Analysis
Above Book Valuation: The market values Geron Corporation's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Geron Corporation's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Geron Corporation (1996–2025)
The table below shows the annual total assets of Geron Corporation from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $570.54 Million | -3.91% |
| 2024-12-31 | $593.78 Million | +50.68% |
| 2023-12-31 | $394.08 Million | +106.78% |
| 2022-12-31 | $190.57 Million | -15.69% |
| 2021-12-31 | $226.03 Million | -16.51% |
| 2020-12-31 | $270.73 Million | +63.57% |
| 2019-12-31 | $165.52 Million | -10.67% |
| 2018-12-31 | $185.28 Million | +67.96% |
| 2017-12-31 | $110.31 Million | -15.31% |
| 2016-12-31 | $130.25 Million | -12.44% |
| 2015-12-31 | $148.76 Million | -13.77% |
| 2014-12-31 | $172.51 Million | +156.16% |
| 2013-12-31 | $67.34 Million | -32.52% |
| 2012-12-31 | $99.80 Million | -37.64% |
| 2011-12-31 | $160.05 Million | -31.48% |
| 2010-12-31 | $233.58 Million | +29.49% |
| 2009-12-31 | $180.38 Million | +2.36% |
| 2008-12-31 | $176.22 Million | -19.50% |
| 2007-12-31 | $218.90 Million | -0.86% |
| 2006-12-31 | $220.80 Million | +9.72% |
| 2005-12-31 | $201.24 Million | +52.60% |
| 2004-12-31 | $131.87 Million | +11.65% |
| 2003-12-31 | $118.11 Million | +94.69% |
| 2002-12-31 | $60.67 Million | -36.95% |
| 2001-12-31 | $96.23 Million | -15.61% |
| 2000-12-31 | $114.03 Million | +79.01% |
| 1999-12-31 | $63.70 Million | +43.15% |
| 1998-12-31 | $44.50 Million | +70.50% |
| 1997-12-31 | $26.10 Million | -9.38% |
| 1996-12-31 | $28.80 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more